Around the same time, the prototype of the Squibb logo was designed. The logo represented product uniformity, purity, efficacy and reliability based on research. By 1924, Bristol-Myers' gross ...

This was the stock's second consecutive day of losses.

Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and growth potential. Learn why BMY stock is a solid ...

Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand ...

This was the stock's third consecutive day of losses.

Bristol Myers (BMY) Squibb announced the Phase 2 TRANSCEND FL trial evaluating Breyanzi, or lisocabtagene maraleucel, in adult patients with relapsed or refractory indolent B-cell non-Hodgkin ...

Bristol Myers Squibb will cut $2 billion in costs by the end of 2027, a move aimed at long-term growth as the company prepares for patent expirations on key treatments, CNBC reported Feb. 6.

With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types. | With another trial win, Bristol Myers Squibb is ...

We recently published a list of 10 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Qorvo ...

Bristol Myers Squibb (BMY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.